



Failed mitochondrial import and impaired proteostasis trigger SUMOylation of mitochondrial proteins

Received for publication, September 14, 2017, and in revised form, November 16, 2017. Published, Papers in Press, November 28, 2017, DOI 10.1074/jbc.M117.817833

Florian Paasch[‡], Fabian den Brave^{†1}, Ivan Psakhye^{‡2},  Boris Pfander^{§3}, and Stefan Jentsch^{††}

From the [‡]Department of Molecular Cell Biology and the [§]Research Group DNA Replication and Genome Integrity, Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany

Edited by George N. DeMartino

Modification by the ubiquitin-like protein SUMO affects hundreds of cellular substrate proteins and regulates a wide variety of physiological processes. While the SUMO system appears to predominantly target nuclear proteins and, to a lesser extent, cytosolic proteins, hardly anything is known about the SUMOylation of proteins targeted to membrane-enclosed organelles. Here, we identify a large set of structurally and functionally unrelated mitochondrial proteins as substrates of the SUMO pathway in yeast. We show that SUMO modification of mitochondrial proteins does not rely on mitochondrial targeting and, in fact, is strongly enhanced upon import failure, consistent with the modification occurring in the cytosol. Moreover, SUMOylated forms of mitochondrial proteins particularly accumulate in HSP70- and proteasome-deficient cells, suggesting that SUMOylation participates in cellular protein quality control. We therefore propose that SUMO serves as a mark for non-functional mitochondrial proteins, which only sporadically arise in unstressed cells but strongly accumulate upon defective mitochondrial import and impaired proteostasis. Overall, our findings provide support for a role of SUMO in the cytosolic response to aberrant proteins.

Posttranslational modification by the small ubiquitin-like modifier (SUMO)⁴ is of fundamental importance for the regulation of a wide variety of physiological processes. Consistent with the large number of cellular SUMO substrates and its crucial roles in cell homeostasis, SUMOylation is essential for via-

bility in most eukaryotes. Moreover, SUMO has been widely implicated in cellular responses to stress, including hypoxic, osmotic, genotoxic, and nutrient stress (1). In particular, SUMOylation is strongly induced under conditions of proteotoxic stress and targets a diverse array of substrate proteins upon protein misfolding caused by heat shock (2–4) or proteasome inhibition (5–7).

Most SUMO substrates identified to date are nuclear proteins (8) and also most SUMO conjugating and deconjugating enzymes show a primarily nuclear localization (9–12). However, SUMOylation is not restricted to the nucleus and several cytosolic SUMO targets have been identified as well (13). Well-studied examples of SUMO substrates outside the nucleus are the septins in budding yeast, which become SUMOylated by the cytosolic pool of the SUMO E3 ligase Siz1 during mitosis (14–19) and deSUMOylated by the SUMO-specific isopeptidase Ulp1 during cytokinesis (14, 15, 20).

Interestingly, SUMO substrates in the cytosol also include proteins that are located at the interfaces of the plasma membrane and cellular organelles such as the nucleus, the endoplasmic reticulum, and mitochondria (13). This group of substrates includes the GTPase DRP1 in mammals, which currently is the only well-characterized SUMO substrate that localizes to mitochondria. DRP1 associates with the cytosolic side of the outer mitochondrial membrane. SUMOylation of DRP1 was found to be mediated by the mitochondrial anchored SUMO E3 ligase MAPL (21) and to promote mitochondrial fission under normal growth conditions (22) as well as during apoptosis (23).

Ubiquitin has also been identified as regulator of mitochondrial homeostasis and has been linked to mitochondrial protein quality control (24, 25). Notably, the ubiquitin-proteasome system was shown to mediate the degradation of nonimported mitochondrial proteins under physiological conditions (26) and acutely upon import failure (26–30). In this scenario, ubiquitin is conjugated to proteins that normally localize to and function within the inner mitochondrial subcompartments (26, 27). By contrast, SUMO modification of proteins from inner mitochondrial subcompartments has not been analyzed to date, even though previous large-scale “SUMOylome” studies have suggested a small number of putative SUMO substrates from these compartments (31–36).

Starting from a mass spectrometry (MS) approach, we provide here evidence that a substantial fraction of the mitochondrial proteome is targeted by the SUMO modification system. We corroborate our MS data by individually confirming the

Research in the S.J. lab is supported by Max Planck Society, Deutsche Forschungsgemeinschaft, Center for Integrated Protein Science Munich, Louis-Jeantet Foundation, and a European Research Council (ERC) Advanced Grant. Research in the B.P. lab is supported by Max Planck Society and Deutsche Forschungsgemeinschaft. This work was also supported by a stipend from EU Marie Curie Training Network (to I.P.). The authors declare that they have no conflicts of interest with the contents of this article.

✂ Author's Choice—Final version free via Creative Commons CC-BY license.

This article contains Figs. S1–S4 and Tables S1–S3.

[†] Deceased, October 29, 2016.

¹ To whom correspondence may be addressed. E-mail: denbrave@biochem.mpg.de.

² Present address: IFOM, the FIRC Institute of Molecular Oncology, Via Adamello 16, 20139 Milan, Italy

³ To whom correspondence may be addressed. E-mail: bpfander@biochem.mpg.de.

⁴ The abbreviations used are: SUMO, small ubiquitin-like modifier; DRP1, dynamin-related protein 1; ³H-SUMO, His-tagged SUMO; HSP70, heat shock protein 70; MTS, matrix-targeting sequence; Ni-NTA, nickel-nitrilotriacetic acid; SC, synthetic complete; SILAC, stable isotope labeling with amino acids in cell culture; YPD, yeast extract peptone dextrose.

SUMOylation of mitochondrial proteins




Figure 1. Mitochondrial proteins are modified by SUMO *in vivo*. A, submitochondrial distribution of 89 potential SUMO substrates, which were identified by a mass spectrometry-based approach. Putative SUMO substrates identified with SUMO acceptor site(s) are indicated in *dark gray*. *dual. loc.*, dual localization; *IMS*, intermembrane space; and *IM*, inner membrane. B–D, mitochondrial matrix proteins Ilv6, Adh3, and Mrpl23 are SUMO substrates. Shown are ^{His}SUMO Ni-NTA pulldowns from wild-type cells and cells expressing epitope-tagged proteins as indicated. His-tagged SUMO (^{His}SUMO) was expressed from the *ADH1* promoter and C-terminally 3HA-tagged Ilv6 (B), 3HA-tagged Adh3 (C), or 3HA-tagged Mrpl23 (D) from the endogenous promoter (B and C) or *ADH1* promoter (D). Proteins were detected by Western blotting using HA epitope- and Pgk1-specific antibodies. Pgk1 SUMOylation was analyzed to control for pulldown efficiency, and unmodified Pgk1 served as control.

SUMO modification of several mitochondrial matrix proteins *in vivo*. In agreement with the presence of SUMO enzymes in the cytosol but not in the mitochondrial matrix, we find that the SUMOylation of mitochondrial proteins does not rely on mitochondrial import. By contrast, our data rather indicate that SUMOylation of mitochondrial proteins is strongly enhanced upon import failure. Moreover, whereas SUMO modification of these substrates occurs only sporadically in unstressed cells, it is particularly induced when canonical components of the proteostasis network, such as the HSP70 system or the proteasome, are defective. Finally, we propose a model in which the SUMO modification pathway targets nonfunctional mitochondrial proteins as an element of cellular protein quality control.

Results

Mitochondrial proteins are modified by SUMO *in vivo*

Following our long-standing interest in the SUMO system, we screened for novel SUMO substrates using a strategy that involves the purification of His-tagged SUMO (^{His}SUMO) conjugates from yeast cells and analysis of the enriched proteins using quantitative mass spectrometry (37, 38). Previous large-scale studies in budding yeast had suggested a small number of mitochondrial proteins as potential SUMO substrates (31–36). Notably, we consistently identified peptides of several different mitochondrial proteins in our ^{His}SUMO purifications. By compiling the results of multiple MS experiments, our approach revealed a set of 89 inner mitochondrial proteins as potential SUMO substrates (Table S1). For 61 of these proteins we also identified a total of 81 SUMOylation sites, further suggesting that these proteins are modified *in vivo* (Table S1).

Among the 89 potential mitochondrial SUMO substrates, we found components of all inner mitochondrial subcompartments (intermembrane space, inner membrane, and matrix) (Fig. 1A). A comparison with the localization of known mitochondrial proteins listed in the Yeast Deletion and Proteomics of Mitochondria (YDPM) database (39) suggested that the number of SUMO substrates from each subcompartment largely scaled with the overall number of proteins in each subcompartment. Seemingly, therefore, submitochondrial localization is not a determinant for SUMO modification. Importantly, only a small fraction of substrates (six proteins) were annotated as having a dual localization (mitochondrial and cytosolic). We therefore conclude that a large number of proteins that function in mitochondria are modified by SUMO *in vivo*.

To ascertain the MS results, we analyzed the SUMOylation of several structurally and functionally unrelated mitochondrial proteins individually. Using denaturing Ni-NTA pulldowns and subsequent Western blot analysis we were able to confirm that these mitochondrial matrix proteins are indeed modified by SUMO. These confirmed SUMO substrates include Ilv6 (Fig. 1B), a protein involved in branched-chain amino acid biosynthesis (40, 41), Adh3 (Fig. 1C), a mitochondrial alcohol dehydrogenase isoform (42, 43), and Mrpl23 (Fig. 1D), a mitochondrial ribosomal protein (44).

We next aimed to identify the SUMO acceptor sites on mitochondrial SUMO substrates. To this end, we systematically replaced individual lysine residues on Ilv6, Adh3, and Mrpl23 to arginine. For Ilv6, this identified lysine 260 as major SUMO acceptor site (Fig. S1, A and B), but additional removal of three




Figure 2. SUMO modification of mitochondrial proteins requires SUMO E3 ligases Siz1 and Siz2. A–C, SUMOylation of Ilv6, Adh3, and Mrpl23 depends on Siz1 and to a lesser extent on Siz2. Denaturing HisSUMO Ni-NTA pull-downs from wild-type (WT) cells and cells lacking Siz1 (*siz1*Δ), Siz2 (*siz2*Δ), or both (*siz1*Δ *siz2*Δ). Strains express C-terminally 3HA-tagged Ilv6 (A), 3HA-tagged Adh3 (B), or 3HA-tagged Mrpl23 (C).

adjacent lysine residues (Lys-218, Lys-284, and Lys-296) in a stepwise manner further reduced SUMOylation and a mutant variant lacking all four lysine residues (Ilv6^{3HA}-K218R, K260R, K284R, K296R termed Ilv6^{3HA}-4KR) did not show any detectable SUMOylation (Fig. S1, A and B). For Adh3, we found lysine 305 as major SUMO acceptor site (Fig. S1, C and D) and for Mrpl23, replacement of the two most C-terminal lysine residues by arginine reduced the levels of SUMO conjugates to less than 50% (Fig. S1, E and F).

SUMOylation of mitochondrial proteins requires the SUMO E3 ligases Siz1 and Siz2

We next asked whether SUMOylation of mitochondrial proteins requires specific SUMO E3 ligases. Analysis of Ilv6 SUMOylation in cells lacking the known SUMO E3 ligases Siz1 (*siz1*Δ) or Siz2 (*siz2*Δ) indicated that the SUMO modification of Ilv6 is catalyzed by Siz1 and to a minor extent by Siz2 (Fig. 2A). Accordingly, Ilv6 SUMOylation was undetectable by Western blotting in samples from cells lacking both Siz1 and Siz2 (*siz1*Δ *siz2*Δ) (Fig. 2A). Moreover, we found strikingly similar roles for Siz1 and Siz2 in the SUMO modification of Adh3 (Fig. 2B) and Mrpl23 (Fig. 2C). Thus, all tested SUMO substrates require the same SUMO E3 ligases of the conserved Siz/PIAS (protein inhibitor of activated STAT) family for modification.

SUMOylation of mitochondrial proteins is enhanced upon import failure

The vast majority of mitochondrial proteins are synthesized on cytosolic ribosomes and subsequently imported into mito-

chondria (45, 46). We therefore asked whether SUMOylation of mitochondrial proteins is linked to the import process or requires the presence of a mitochondrial targeting signal. Classical mitochondrial targeting signals are N-terminal presequences, which in most cases are proteolytically removed from mitochondrial precursor proteins during import. Presequences frequently target proteins into the mitochondrial matrix and therefore are also referred to as matrix-targeting sequences (MTS) (45). Accordingly, we generated an Ilv6 mutant variant (MTSΔ-Ilv6^{3HA}), which lacks the N-terminal MTS (amino acids 1–24) required for mitochondrial import (Fig. 3A). Microscopic analysis of corresponding GFP fusion proteins demonstrated that removal of the 24 N-terminal amino acids of Ilv6 is indeed sufficient to prevent mitochondrial import, thereby causing a presumably cytosolic localization of the mutant protein variant (Fig. S2, A and B). Importantly, this mutant was efficiently SUMOylated (Fig. 3B) and the modification was again dependent on the SUMO E3 ligases Siz1 and Siz2 (Fig. S2C) and occurred at a similar set of SUMO acceptor sites as for wild-type Ilv6 (Fig. S2D). Therefore, SUMO modification of Ilv6 does not rely on mitochondrial import and does not require the presence of an MTS. In fact, MTS deletion even strongly enhanced the SUMOylation of Ilv6 (Fig. 3B), indicating that SUMO modification is induced by import failure.

We also analyzed an import-incompetent variant of Adh3 (MTSΔ-Adh3^{3HA}) (Fig. 3C). Again, SUMO modification of the import-incompetent variant was enhanced compared with the wild-type protein (Fig. 3D). Furthermore, SUMOylation of

SUMOylation of mitochondrial proteins




Figure 3. SUMO modification of mitochondrial proteins is enhanced upon import failure. A–D, SUMOylation of Ilv6 and Adh3 is enhanced in the absence of a mitochondrial targeting signal. A and C, schematic representation of Ilv6^{3HA} (A) or Adh3^{3HA} (C) and corresponding mutant variants lacking the matrix-targeting sequence (MTS). ACT domain, named after aspartate kinase, chorismate mutase, TyrA; ALS_{ss_C} domain, acetolactate synthase, small subunit, C-terminal domain; zinc-binding DH domain, zinc-binding dehydrogenase domain. B and D, denaturing His-SUMO Ni-NTA pulldowns from cells harboring plasmids that express wild-type Ilv6 (B) or Adh3 (D) and corresponding import-incompetent mutant variants as indicated from the *GAL1* promoter. Data information: The ratios of SUMOylated/unmodified proteins (B and D) were determined by Western blot quantification using ImageJ and normalized to the wild-type proteins. E, a SUMOylated Ilv6 precursor accumulates upon inactivation of mitochondrial HSP70 (*Ssc1*). Denaturing His-SUMO Ni-NTA pulldowns from wild-type (WT) and temperature-sensitive *ssc1-3* cells expressing C-terminally 3HA-tagged Ilv6 from the endogenous promoter. Cells were grown at 25 °C and shifted to 37 °C for 1 h. Bands corresponding to the unmodified or monoSUMOylated precursor protein (p) or mature form (m) are labeled.

import-incompetent Adh3 also required the SUMO E3 ligases Siz1 and Siz2 (Fig. S2E) and the predominantly targeted lysine 305 (Fig. S2F), similar to wild-type Adh3. We therefore conclude that import-incompetent mutant variants of mitochondrial proteins are SUMOylated with requirements as wild-type substrates, but that deletion of targeting sequences strongly

enhances the modification. This may suggest that SUMOylation of wild-type proteins specifically occurs upon sporadic mistargeting in unstressed cells and under conditions where mitochondrial protein import is impaired. Indeed, we observed an accumulation of SUMOylated Ilv6 precursors (p) in strains defective in mitochondrial import (Fig. 3E), which harbor a

temperature-sensitive mutant variant of mitochondrial HSP70 (*ssc1-3*) (47). Furthermore, we specifically observed the accumulation of SUMOylated Ilv6 precursors in the *ssc1-3* mutant, whereas in wild-type cells Ilv6-SUMO conjugates appeared to be proteolytically processed (Fig. 3E; note the shift of the precursor (p) compared with the mature form (m)). This indicates that the major pool of Ilv6-SUMO conjugates in unstressed wild-type cells possesses a proteolytically processed N terminus. It is therefore conceivable that these protein species have at some point initiated mitochondrial import, but that they become modified by SUMO in the cytosol.

SUMOylation of mitochondrial proteins is regulated by the SSA family of HSP70 chaperones

Based on our observation that the SUMOylation of mitochondrial proteins can occur in the cytosol, we speculated that the modification might be affected by factors which bind non-imported mitochondrial precursor proteins. Several factors are involved in posttranslational protein import into mitochondria (48–50), of which the SSA family HSP70 proteins (*Ssa1–4*) are of particular importance in budding yeast (51, 52). We therefore used cells in which HSP70 function was diminished by deletion of three out of four SSA genes (*ssa2Δ ssa3Δ ssa4Δ*) and additional expression of either wild-type *SSA1* or the hypomorphic mutant variant *ssa1-45* (53). HSP70 chaperones have been shown to bind to mitochondrial precursor proteins, to maintain them in an import-competent state, and to prevent their aggregation (52, 54, 55). Consistently, we observed an increased aggregation propensity of the Ilv6 precursor (p) compared with the processed mitochondrial form (m) of the protein (Fig. S3A). Moreover, the levels of the Ilv6 precursor were mildly increased when HSP70 activity was compromised (Fig. S3A). This indicates that SSA family chaperones are indeed involved in the mitochondrial import of Ilv6. Strikingly, we also detected a strong accumulation of SUMOylated Ilv6 precursors in SSA mutants, particularly in *ssa1-45* cells (Fig. 4A), which was suppressed by ectopic expression of *Ssa1* from the strong constitutive *ADH1* promoter (Fig. S3, B and C). Notably, in addition to monoSUMOylated Ilv6, we detected further bands with a slower migration behavior in *ssa1-45* cells, suggesting the presence of Ilv6 species modified with multiple SUMO moieties (Fig. 4A). Likewise, the levels of SUMOylated Adh3 were elevated in the *ssa1-45* background (Fig. 4B), indicating that a functionally compromised SSA chaperone system generally causes enhanced SUMO modification of mitochondrial proteins. Interestingly, when we further characterized Ilv6 and Adh3 SUMOylation in SSA mutants, we additionally noticed the modification of lysine residues, which were not detectable by Western blotting in wild-type cells (Fig. 4, C and D and Fig. S3D).

To test if the enhanced SUMOylation of mitochondrial proteins in SSA mutant cells would simply result from an import defect, we introduced the import-incompetent variant of Adh3 (MTSΔ-Adh3^{3HA}) in *SSA1* and *ssa1-45* cells (Fig. 4E). Strikingly, however, we observed a further enhancement of Adh3 SUMOylation, suggesting that import failure and SSA deficiency exert an additive effect on the SUMOylation of mitochondrial proteins. We thus conclude that defective mitochon-

drial import and functional impairment of the SSA HSP70 system are additive triggers for SUMOylation of mitochondrial proteins.

Enhanced SUMOylation of mitochondrial proteins in proteasome mutants

Molecular chaperones are central hubs of cellular protein quality control. In addition to their function in protein folding, they also act as decision makers and target terminally misfolded proteins for degradation by the ubiquitin-proteasome system (56, 57). We therefore asked whether the SUMO modification of mitochondrial proteins would be influenced by the cells' ability to degrade proteins via the proteasome. To abrogate proteasome function, we took advantage of the *cim3-1* temperature-sensitive mutant, which induces a defect in the 19S regulatory proteasome subunit Rpt6 (58), or used the proteasome inhibitor MG132.

Strikingly, when we analyzed SUMO conjugates in *cim3-1* cells, we found an accumulation of multiple SUMOylated species of Ilv6 (Fig. 5A), Adh3 (Fig. 5B), and Mrpl23 (Fig. 5C), indicating that proteasomal degradation strongly impacts the SUMOylation of mitochondrial proteins. Moreover, as judged from the SUMOylation patterns of Adh3 and Ilv6 in *cim3-1* cells, which were similar to those observed in SSA mutants, proteasome inhibition also led to an accumulation of SUMOylated precursor proteins. This idea was further confirmed by analysis of Ilv6 SUMOylation in cells treated with the proteasome inhibitor MG132 (Fig. S4A). Notably, we consistently detected a slight accumulation of precursor proteins of Ilv6 and Adh3 in *cim3-1* and MG132-treated cells (Fig. 5, A and B and Fig. S4A), which is in line with previous studies that have implicated the ubiquitin-proteasome system in the clearance of non-imported mitochondrial proteins from the cytosol (26–30). Taken together, these observations suggest that SUMOylation targets nonimported mitochondrial precursor proteins, which fail to be degraded in response to proteasome inhibition.

In addition to our observation of increased mitochondrial protein SUMOylation upon proteasome inhibition, we also tested whether the SUMO conjugates themselves would be substrates of the proteasome and therefore stabilized in proteasome mutant cells. Therefore, we combined a translation shut-off experiment (cycloheximide shut-off) with denaturing NiNTA pulldowns to monitor SUMOylated Ilv6 over time. First, we observed that the unmodified Ilv6 precursor is rapidly degraded in wild-type cells, but strongly stabilized in the *cim3-1* mutant (Fig. 5D; see *inputs*). This indicates that Ilv6 precursors, which fail to be imported into mitochondria, are degraded in a proteasome-dependent manner. Second, we observed that SUMOylated Ilv6 is rapidly turned over in wild-type cells and almost completely stabilized in *cim3-1* cells (Fig. 5D; see *NiNTA pulldowns*). Overall, SUMOylated forms of Ilv6 are turned over by the proteasome in remarkably similar fashion as the Ilv6 precursor.

Consistent with the proteasomal clearance of nonimported Ilv6 species, we found that the import-incompetent Ilv6 mutant variant, which lacks its MTS (MTSΔ-Ilv6^{3HA}), is degraded in a proteasome-dependent manner (Fig. S4B). However, removal of the four major SUMOylation sites or even completely abol-

SUMOylation of mitochondrial proteins




Figure 4. SUMO modification of mitochondrial proteins is enhanced in SSA family HSP70 mutant cells. A and B, inactivation of Ssa1–4 causes accumulation of Ilv6 (A) and Adh3 (B) SUMO conjugates and of the corresponding precursors. Denaturing HisSUMO Ni-NTA pull-downs from wild-type (WT), SSA1 (SSA1 ssa2 Δ ssa3 Δ ssa4 Δ) and ssa1-45 (ssa1-45 ssa2 Δ ssa3 Δ ssa4 Δ) cells expressing 3HA-tagged Ilv6 (A) or 3HA-tagged Adh3 (B) from the endogenous promoter. Bands corresponding to the unmodified or monoSUMOylated precursor proteins (p) or mature forms (m) are labeled. C and D, SUMO modification after SSA impairment occurs via specific and additionally accessible modification sites. Denaturing HisSUMO Ni-NTA pull-downs from SSA1 and ssa1-45 cells expressing 3HA-tagged wild-type (WT) Ilv6 (C) or 3HA-tagged wild-type Adh3 (D) and the indicated lysine to arginine mutants from the ADH1 (C) or TDH3 (D) promoter. E, SSA impairment and deletion of the Adh3 MTS cause an additive enhancement in Adh3 SUMOylation. Denaturing HisSUMO Ni-NTA pull-downs from SSA1 and ssa1-45 cells harboring plasmids that express wild-type (WT) or MTS-lacking (MTS Δ) 3HA-tagged Adh3 from the TDH3 promoter. Bands corresponding to the Adh3 precursor (p) or mature form (m) are labeled.

ishing SUMO modification by deletion of the SUMO E3 ligases Siz1 and Siz2 did not noticeably delay the degradation of import-incompetent Ilv6 (Fig. S4, C and D). Therefore, although we cannot exclude that a minor pool of nonimported Ilv6 is targeted for degradation in a SUMO-dependent manner, this indicates that SUMOylation is not used as a widespread

signal for proteasomal clearance of the majority of nonimported mitochondrial proteins. We conclude that SUMO rather serves as a mark for nonimported mitochondrial proteins, particularly in the absence of proteasomal degradation.

Given our observation that SUMOylation of mitochondrial proteins is also enhanced upon import failure, we predicted




Figure 5. Accumulation of SUMO-modified mitochondrial proteins in proteasome mutants. A–C, SUMO-modified forms of mitochondrial proteins accumulate under conditions of proteasome impairment. Denaturing ^{His}SUMO Ni-NTA pull-downs from wild-type (*WT*) and *cim3-1* cells. The strains express 3HA-tagged Ilv6 (A) or 3HA-tagged Adh3 (B) from their endogenous promoters or harbor plasmids that express 3HA-tagged Mrp123 (C) from the *ADH1* promoter. Bands corresponding to the unmodified or monoSUMOylated precursor proteins (*p*) or mature forms (*m*) are labeled. D, Ilv6 precursors and SUMOylated Ilv6 species are stabilized in the *cim3-1* mutant. Expression shut-off assay of Ilv6-SUMO conjugates. Yeast cells were treated with 0.5 mg/ml cycloheximide (CHX) and samples were harvested at the indicated time points. Denaturing Ni-NTA pull-downs were performed to isolate ^{His}SUMO conjugates from cells expressing 3HA-tagged Ilv6 from the endogenous promoter. Bands corresponding to the unmodified or monoSUMOylated precursor protein (*p*) or mature form (*m*) are labeled. E, proteasome impairment and deletion of the Adh3 MTS cause an additive enhancement in Adh3 SUMOylation. Denaturing ^{His}SUMO Ni-NTA pull-downs from wild-type (*WT*) and *cim3-1* cells harboring plasmids that express Adh3 variants as indicated from the *ADH1* promoter.

that SUMOylation should be strongly augmented upon expression of an MTS-lacking mutant protein in *cim3-1* cells. Indeed, multiple SUMOylated species of the import-incompetent Adh3 mutant variant (MTSΔ-Adh3^{3HA}) strongly accumulated in proteasome mutants (Fig. S4, E and F) and MTS deletion enhanced the SUMOylation of Adh3 in both wild-type and *cim3-1* cells (Fig. 5E). We thus conclude that the SUMOylation of mitochondrial proteins is additively triggered upon import failure and inhibition of the proteasomal degradation system.

Discussion

Our study identifies SUMO modification as an element of cellular protein quality control that acts on mitochondrial proteins. This adds to the growing list of experimental evidence that suggests functions of SUMO in cellular stress responses (1). In particular, we find that SUMOylation of mitochondrial proteins is induced upon failed mitochondrial import and when

HSP70- or proteasome-dependent surveillance systems are defective. We therefore propose that SUMO serves as a mark for nonfunctional and nonimported, perhaps even import-incompetent, mitochondrial proteins.

Interestingly, SUMOylation is detectable on small pools of processed mitochondrial proteins even under normal growth conditions. As judged from the apparent cleavage of their N-terminal MTS, these proteins seem to initiate or to have initiated import. Currently it is unclear whether SUMO modification occurs before, concomitant with, or after the attempted import event. It can even be speculated, given that mitochondrial proteins are typically imported in an unfolded and extended conformation (59), that the attachment of a folded SUMO moiety to a precursor protein may stall the translocation.

In agreement with a function of SUMO in the quality control of cytosolic proteins, we also provide evidence that SUMOyla-

SUMOylation of mitochondrial proteins

tion of mitochondrial proteins does not rely on mitochondrial import. Thus, SUMOylation appears to occur outside their native environment, where mislocalized proteins are potential sources of cellular stress. Indeed, recent reports have highlighted that accumulation of nonimported mitochondrial precursor proteins (termed mitochondrial precursor overaccumulation stress (mPOS)) is a challenge to cellular proteostasis (60, 61). These studies furthermore show that cells react to mitochondrial precursor overaccumulation stress with specific compensatory mechanisms such as a reduction of cytosolic translation and an increase in proteasome activity. We speculate that SUMOylation of mitochondrial proteins might be a further protective mechanism involved in the cytosolic proteostatic responses to mitochondrial stress (62).

Protein modification by SUMO has also been implicated in the quality control of other proteins including transcriptional regulators (63) and aggregation-prone proteins involved in neurodegenerative diseases (64, 65). It has been proposed that SUMO may act as a “solubility enhancer” (65), which reduces protein aggregation (66–71) and enables clearance of aggregates by the ubiquitin-proteasome system via recruitment of specific SUMO-binding factors (72). Notably, fostering physical interactions between SUMOylated proteins and binding partners that harbor so-called SUMO-interacting motifs (SIMs) is apparently one of the most prominent functions of SUMO (13, 73). It can therefore be speculated that SUMO modification will determine the fate of nonimported mitochondrial proteins by the recruitment of specific SUMO-interacting motif-containing interaction partners, which in turn could affect the targeting competence and solubility of a modified protein. Moreover, although SUMOylation is apparently not an essential requirement for the proteasomal degradation of nonimported mitochondrial proteins (Fig. S4, C and D), such factors might contribute to the clearance of specific protein pools and could target species that have failed to be degraded by the common ubiquitin-proteasome-dependent mechanism. At any rate, our data provide the first evidence for SUMO acting on aberrant and nonimported mitochondrial proteins.

Finally, we emphasize that SUMO modification, as we describe it here for mitochondrial substrates, will most likely not discriminate between mislocalized proteins based on their original destination. We therefore reason that the modification is unlikely to be specific for mitochondrial proteins and that nonimported proteins of other organelles could become modified in a similar fashion. Accordingly, it can be envisioned that such substrates will arise in particular upon organelle dysfunction, mistargeting, or stress-induced protein damage. Consistent with this idea, SUMOylation is strongly induced in the nucleus upon proteotoxic stress (3).

Studying the functions of SUMO in proteostasis is challenged by the multiple other ways through which SUMO regulates protein function. For proteins within their native environment it is therefore difficult to dissect quality control and other functions of SUMO. By contrast, SUMO modification of mitochondrial substrates appears to occur outside of their functional compartment. Thus, our study not only brings renewed attention to the multifaceted roles of SUMO as a component of the cellular proteostasis network but also opens a new

opportunity for revealing the functions of SUMO in protein quality control.

Experimental procedures

Yeast strains and plasmids

All yeast (*Saccharomyces cerevisiae*) strains and plasmids used in this study are listed in Tables S2 and S3, respectively.

Identification of SUMO substrates by SILAC mass spectrometry

Enrichment of SUMO conjugates from yeast cells expressing ^{His}SUMO followed by SILAC-based mass spectrometric analysis has been described previously (37, 38). In brief, yeast cells deficient in the biosynthesis of lysine and arginine (*lys1Δ arg4Δ*) were grown in synthetic complete (SC) media containing either unlabeled or heavy isotope-labeled lysine and arginine (Lys8, Arg10). ^{His}SUMO conjugates were isolated using denaturing Ni-NTA pull-downs and separated on NuPAGE Bis-Tris Gels (4–12%) (Thermo Fisher Scientific). Gels were stained with Coomassie Blue and single lanes were excised in form of 10 separate gel slices. Subsequently, proteins were digested with trypsin or thermolysin and analyzed by LTQ Orbitrap mass spectrometry (74) and MaxQuant software (75).

SUMO-modified proteins were identified based on two criteria. The first was the enrichment in samples of yeast cells expressing ^{His}SUMO compared with untagged SUMO (SILAC ratios above 2). The second was the detection of SUMO attachment sites as described previously (38).

We would like to note that the list of potential SUMO substrates presented here (Table S1) represents a compiled dataset from multiple mass spectrometry experiments.

Yeast techniques and molecular cloning

Yeast deletion mutants and chromosomally tagged strains were generated by common PCR-based strategies, genetic crosses, and standard techniques (76, 77). Yeast strains were inoculated from fresh overnight cultures and grown using standard growth conditions (78). Typically, cells were cultured at 30 °C in yeast extract peptone dextrose (YPD) or SC media containing glucose (2%) as carbon source. For the expression of genes under the *GAL1* promoter, yeast cells (W303 background) were grown in medium containing 2% raffinose, and 2% galactose was added to induce protein expression. Strains harboring a temperature-sensitive *SSC1* allele (*ssc1-3*) were grown at 25 °C and shifted to 37 °C as indicated. The hypomorphic *SSA1* and *CIM3* mutants used in this study (*ssa1-45* and *cim3-1*) display phenotypes already at the permissive temperature. These strains including the corresponding wild-type controls were grown at 25 °C. For the qualitative analysis of growth phenotypes, exponentially growing yeast cultures were adjusted to an A_{600} of 1, and six 5-fold serial dilutions were spotted on SC agar plates. The plates were scanned after 2–3 days' incubation at 25 °C and 37 °C, respectively.

Plasmid constructs for the expression of ^{His}SUMO under control of the *ADHI* promoter have been described previously (79, 80). Standard cloning techniques were used to generate constructs for the expression of HA-tagged proteins and N-terminally truncated mutant variants. Point mutations were introduced using PCR-based site-directed mutagenesis.

Protein techniques, cellular fractionation, and Western blotting

Total cell extracts were prepared by TCA precipitation (76) and Ni-NTA pulldowns of ^{His}SUMO conjugates under denaturing conditions were performed as described previously (37). SUMOylation of mitochondrial proteins in different yeast strains was initially analyzed with C-terminally 3HA-tagged proteins expressed from their endogenous promoters (Ilv6^{3HA} and Adh3^{3HA}). To more quantitatively assess SUMOylation, expression systems under control of the *ADH1*, *GAL1*, or *TDH3* promoters were additionally used.

For ^{His}SUMO Ni-NTA pulldowns combined with expression shut-off assays, cells were grown in YPD medium, shifted to 37 °C for 60 min, and treated with 0.5 mg/ml cycloheximide (CHX) dissolved in YPD medium prior to the experiment. Cells were harvested at the time points indicated in the respective experiment and denaturing Ni-NTA pulldowns were performed to isolate ^{His}SUMO conjugates.

Cellular fractionations were performed as described previously (81) with minor modifications. Cells were lysed by bead-beating in lysis buffer (100 mM HEPES pH 7.5, 1% Triton X-100, 300 mM NaCl, EDTA-free protease inhibitor mixture (Roche), 1 mg/ml Pefabloc SC (Roche)) using zirconia/silica beads (Bio Spec Products, Inc., Bartlesville, OK) and a multi-tube bead-beater (MM301, Retsch Technology, Haan, Germany). Cellular lysates were cleared by centrifugation (2000 × *g*, 10 min, 4 °C) and the resulting total cell extracts (T fraction) were fractionated by centrifugation (16,000 × *g*, 10 min, 4 °C) to yield soluble (S fraction) and insoluble pellet (P fraction) fractions.

Proteins from cell extracts, cell fractions, or isolated by Ni-NTA pulldowns were separated on NuPAGE Bis-Tris gels (12% or 4–12%) (Thermo Fisher Scientific) and analyzed using standard Western blotting techniques.

Cycloheximide shut-off assays

To monitor the degradation of import-incompetent Ilv6 (MTSD-Ilv6^{3HA}) expressed from the *GAL1* promoter, cells were grown at 30 °C in SC medium containing 2% raffinose as carbon source. Protein expression was induced by addition of 2% galactose for 1 h and cells were shifted to 37 °C. Optionally, cells (*pdr5Δ*) were treated with 50 μM MG132 dissolved in DMSO. After 1 h at 37 °C cells were resuspended in YPD medium containing 0.5 mg/ml cycloheximide and samples of 1 A₆₀₀ were taken at different time points. Cell extracts were prepared by TCA precipitation and analyzed by Western blotting.

Fluorescence microscopy

Yeast cells (W303 background) were grown at 30 °C in SC medium containing 2% raffinose as carbon source. Cells were complemented with plasmids expressing full-length Ilv6^{GFP} from the endogenous promoter or import-incompetent Ilv6 (MTSD-Ilv6^{GFP}) from the *GAL1* promoter. Protein expression was induced by addition of 2% galactose for 1 h. Cells were then transferred into a CellCarrier-96 black polystyrene microplate (PerkinElmer Life Sciences) and stained using Calcofluor White (Sigma-Aldrich). Images were captured at room temperature using an Opera Phenix HCS confocal microscope

(PerkinElmer Life Sciences) equipped with an Olympus 63× water NA 1.15 objective.

Antibodies

Polyclonal Smt3-specific antibodies were raised in rabbits and have been described previously (79). Monoclonal (F-7) and polyclonal (Y-11) antibodies directed against the HA epitope were purchased from Santa Cruz Biotechnology (Dallas, TX). The monoclonal Pgl1 (22C5D8) and Dpm1 (5C5) antibodies were from Thermo Fisher Scientific and the monoclonal HSP70 (BB70) antibody was from Enzo Life Sciences (Farmingdale, NY).

Software

GraphPad Prism (GraphPad Software, La Jolla, CA) was used for data presentation (Fig. 1A) and ImageJ was used for Western blot quantification (Fig. 3, B and D). Microscopic imaging data were acquired and evaluated using Harmony 4.5 high-content imaging and analysis software (PerkinElmer Life Sciences).

Author contributions—F.P. and S.J. conceived the study. F.P., F.d.B., I.P., B.P., and S.J. designed experiments and analyzed data. I.P. conducted and together with F.d.B. evaluated the initial mass spectrometric analysis. F.P. performed all other experiments. F.P., F.d.B., and B.P. wrote the manuscript.

Acknowledgments—We thank F.U. Hartl, W. Neupert, L. Cairo, M. Höpfler, F. Wilfling, and members of the Jentsch and Pfander labs for fruitful discussions and critical comments on the manuscript; W. Neupert for strains; K. Straßer and A. Straßer for technical assistance; J. Rech for help with fluorescence microscopy; and the Biochemistry Core Facility of the Max Planck Institute of Biochemistry for mass spectrometry analysis.

References

- Enserink, J. M. (2015) Sumo and the cellular stress response. *Cell Div.* **10**, 4 [CrossRef Medline](#)
- Golebiowski, F., Matic, I., Tatham, M. H., Cole, C., Yin, Y., Nakamura, A., Cox, J., Barton, G. J., Mann, M., and Hay, R. T. (2009) System-wide changes to SUMO modifications in response to heat shock. *Sci. Signal.* **2**, ra24 [CrossRef Medline](#)
- Seifert, A., Schofield, P., Barton, G. J., and Hay, R. T. (2015) Proteotoxic stress reprograms the chromatin landscape of SUMO modification. *Sci. Signal.* **8**, rs7 [CrossRef Medline](#)
- Niskanen, E. A., Malinen, M., Sutinen, P., Toropainen, S., Paakinaho, V., Vihervaara, A., Joutsen, J., Kaikkonen, M. U., Sistonen, L., and Palvimo, J. J. (2015) Global SUMOylation on active chromatin is an acute heat stress response restricting transcription. *Genome Biol.* **16**, 153 [CrossRef Medline](#)
- Castorálová, M., Bezinová, D., Svěda, M., Lipov, J., Ruml, T., and Knejzlík, Z. (2012) SUMO-2/3 conjugates accumulating under heat shock or MG132 treatment result largely from new protein synthesis. *Biochim. Biophys. Acta* **1823**, 911–919 [CrossRef Medline](#)
- Tatham, M. H., Matic, I., Mann, M., and Hay, R. T. (2011) Comparative proteomic analysis identifies a role for SUMO in protein quality control. *Sci. Signal.* **4**, rs4 [CrossRef Medline](#)
- Schimmel, J., Larsen, K. M., Matic, I., van Hagen, M., Cox, J., Mann, M., Andersen, J. S., and Vertegaal, A. C. (2008) The ubiquitin-proteasome system is a key component of the SUMO-2/3 cycle. *Mol. Cell Proteomics* **7**, 2107–2122 [CrossRef Medline](#)
- Hendriks, I. A., and Vertegaal, A. C. (2016) A comprehensive compilation of SUMO proteomics. *Nat. Rev. Mol. Cell Biol.* **17**, 581–595 [CrossRef Medline](#)

SUMOylation of mitochondrial proteins

9. Hickey, C. M., Wilson, N. R., and Hochstrasser, M. (2012) Function and regulation of SUMO proteases. *Nat. Rev. Mol. Cell Biol.* **13**, 755–766 [CrossRef Medline](#)
10. Johnson, E. S. (2004) Protein modification by SUMO. *Annu. Rev. Biochem.* **73**, 355–382 [CrossRef Medline](#)
11. Seeler, J. S., and Dejean, A. (2003) Nuclear and unclear functions of SUMO. *Nat. Rev. Mol. Cell Biol.* **4**, 690–699 [CrossRef Medline](#)
12. Flotho, A., and Melchior, F. (2013) Sumoylation: A regulatory protein modification in health and disease. *Annu. Rev. Biochem.* **82**, 357–385 [CrossRef Medline](#)
13. Geiss-Friedlander, R., and Melchior, F. (2007) Concepts in sumoylation: A decade on. *Nat. Rev. Mol. Cell Biol.* **8**, 947–956 [CrossRef Medline](#)
14. Makhnevych, T., Ptak, C., Lusk, C. P., Aitchison, J. D., and Wozniak, R. W. (2007) The role of karyopherins in the regulated sumoylation of septins. *J. Cell Biol.* **177**, 39–49 [CrossRef Medline](#)
15. Johnson, E. S., and Blobel, G. (1999) Cell cycle-regulated attachment of the ubiquitin-related protein SUMO to the yeast septins. *J. Cell Biol.* **147**, 981–994 [CrossRef Medline](#)
16. Johnson, E. S., and Gupta, A. A. (2001) An E3-like factor that promotes SUMO conjugation to the yeast septins. *Cell* **106**, 735–744 [CrossRef Medline](#)
17. Takahashi, Y., Iwase, M., Konishi, M., Tanaka, M., Toh-e, A., and Kikuchi, Y. (1999) Smt3, a SUMO-1 homolog, is conjugated to Cdc3, a component of septin rings at the mother-bud neck in budding yeast. *Biochem. Biophys. Res. Commun.* **259**, 582–587 [CrossRef Medline](#)
18. Takahashi, Y., Kahyo, T., Toh-e, A., Yasuda, H., and Kikuchi, Y. (2001) Yeast Ull1/Siz1 is a novel SUMO1/Smt3 ligase for septin components and functions as an adaptor between conjugating enzyme and substrates. *J. Biol. Chem.* **276**, 48973–48977 [CrossRef Medline](#)
19. Takahashi, Y., Toh-e, A., and Kikuchi, Y. (2001) A novel factor required for the SUMO1/Smt3 conjugation of yeast septins. *Gene* **275**, 223–231 [CrossRef Medline](#)
20. Takahashi, Y., Mizoi, J., Toh-e, A., and Kikuchi, Y. (2000) Yeast Ulp1, an Smt3-specific protease, associates with nucleoporins. *J. Biochem.* **128**, 723–725 [CrossRef Medline](#)
21. Braschi, E., Zunino, R., and McBride, H. M. (2009) MAPL is a new mitochondrial SUMO E3 ligase that regulates mitochondrial fission. *EMBO Rep.* **10**, 748–754 [CrossRef Medline](#)
22. Harder, Z., Zunino, R., and McBride, H. (2004) Sumo1 conjugates mitochondrial substrates and participates in mitochondrial fission. *Curr. Biol.* **14**, 340–345 [CrossRef Medline](#)
23. Wasiaik, S., Zunino, R., and McBride, H. M. (2007) Bax/Bak promote sumoylation of DRP1 and its stable association with mitochondria during apoptotic cell death. *J. Cell Biol.* **177**, 439–450 [CrossRef Medline](#)
24. Escobar-Henriques, M., and Langer, T. (2014) Dynamic survey of mitochondria by ubiquitin. *EMBO Rep.* **15**, 231–243 [CrossRef Medline](#)
25. Bragoszewski, P., Turek, M., and Chacinska, A. (2017) Control of mitochondrial biogenesis and function by the ubiquitin-proteasome system. *Open Biol.* **7**, 170007 [CrossRef Medline](#)
26. Bragoszewski, P., Gornicka, A., Sztolszterer, M. E., and Chacinska, A. (2013) The ubiquitin-proteasome system regulates mitochondrial intermembrane space proteins. *Mol. Cell Biol.* **33**, 2136–2148 [CrossRef Medline](#)
27. Habelhah, H., Laine, A., Erdjument-Bromage, H., Tempst, P., Gershwin, M. E., Bowtell, D. D., and Ronai, Z. (2004) Regulation of 2-oxoglutarate (α -ketoglutarate) dehydrogenase stability by the RING finger ubiquitin ligase Siah. *J. Biol. Chem.* **279**, 53782–53788 [CrossRef Medline](#)
28. Radke, S., Chander, H., Schäfer, P., Meiss, G., Krüger, R., Schulz, J. B., and Germain, D. (2008) Mitochondrial protein quality control by the proteasome involves ubiquitination and the protease Omi. *J. Biol. Chem.* **283**, 12681–12685 [CrossRef Medline](#)
29. Pearce, D. A., and Sherman, F. (1997) Differential ubiquitin-dependent degradation of the yeast apo-cytochrome c isozymes. *J. Biol. Chem.* **272**, 31829–31836 [CrossRef Medline](#)
30. Itakura, E., Zavodszky, E., Shao, S., Wohlever, M. L., Keenan, R. J., and Hegde, R. S. (2016) Ubiquitins chaperone and triage mitochondrial membrane proteins for degradation. *Mol. Cell* **63**, 21–33 [CrossRef Medline](#)
31. Denison, C., Rudner, A. D., Gerber, S. A., Bakalarski, C. E., Moazed, D., and Gygi, S. P. (2005) A proteomic strategy for gaining insights into protein sumoylation in yeast. *Mol. Cell Proteomics* **4**, 246–254 [CrossRef Medline](#)
32. Wohlschlegel, J. A., Johnson, E. S., Reed, S. I., and Yates, J. R., 3rd. (2004) Global analysis of protein sumoylation in *Saccharomyces cerevisiae*. *J. Biol. Chem.* **279**, 45662–45668 [CrossRef Medline](#)
33. Panse, V. G., Hardeland, U., Werner, T., Kuster, B., and Hurt, E. (2004) A proteome-wide approach identifies sumoylated substrate proteins in yeast. *J. Biol. Chem.* **279**, 41346–41351 [CrossRef Medline](#)
34. Zhou, W., Ryan, J. J., and Zhou, H. (2004) Global analyses of sumoylated proteins in *Saccharomyces cerevisiae*. Induction of protein sumoylation by cellular stresses. *J. Biol. Chem.* **279**, 32262–32268 [CrossRef Medline](#)
35. Hannich, J. T., Lewis, A., Kroetz, M. B., Li, S. J., Heide, H., Emili, A., and Hochstrasser, M. (2005) Defining the SUMO-modified proteome by multiple approaches in *Saccharomyces cerevisiae*. *J. Biol. Chem.* **280**, 4102–4110 [CrossRef Medline](#)
36. Wykoff, D. D., and O’Shea, E. K. (2005) Identification of sumoylated proteins by systematic immunoprecipitation of the budding yeast proteome. *Mol. Cell Proteomics* **4**, 73–83 [CrossRef Medline](#)
37. Psakhye, I., and Jentsch, S. (2016) Identification of substrates of protein-group SUMOylation. *Methods Mol. Biol.* **1475**, 219–231 [CrossRef Medline](#)
38. Psakhye, I., and Jentsch, S. (2012) Protein group modification and synergy in the SUMO pathway as exemplified in DNA repair. *Cell* **151**, 807–820 [CrossRef Medline](#)
39. Prokisch, H., Scharfe, C., Camp, D. G., 2nd, Xiao, W., David, L., Andreoli, C., Monroe, M. E., Moore, R. J., Gritsenko, M. A., Kozany, C., Hixson, K. K., Mottaz, H. M., Zischka, H., Ueffing, M., Herman, Z. S., Davis, R. W., Meitinger, T., Oefner, P. J., Smith, R. D., and Steinmetz, L. M. (2004) Integrative analysis of the mitochondrial proteome in yeast. *PLoS Biol.* **2**, e160 [CrossRef Medline](#)
40. Cullin, C., Baudin-Baillieu, A., Guillemet, E., and Ozier-Kalogeropoulos, O. (1996) Functional analysis of YCL09C: Evidence for a role as the regulatory subunit of acetolactate synthase. *Yeast* **12**, 1511–1518 [CrossRef Medline](#)
41. Pang, S. S., and Duggleby, R. G. (1999) Expression, purification, characterization, and reconstitution of the large and small subunits of yeast aceto-hydroxyacid synthase. *Biochemistry* **38**, 5222–5231 [CrossRef Medline](#)
42. Sugar, J., Schimpffessel, L., Rozen, E., and Crokaert, R. (1970) The mitochondrial alcohol dehydrogenase of the yeast “*Saccharomyces cerevisiae*.” *Arch. Int. Physiol. Biochim.* **78**, 1009–1010 [Medline](#)
43. Lutstorff, U., and Megnet, R. (1968) Multiple forms of alcohol dehydrogenase in *Saccharomyces cerevisiae*. I. Physiological control of ADH-2 and properties of ADH-2 and ADH-4. *Arch. Biochem. Biophys.* **126**, 933–944 [CrossRef Medline](#)
44. Kitakawa, M., Graack, H. R., Grohmann, L., Goldschmidt-Reisin, S., Herfurth, E., Wittmann-Liebold, B., Nishimura, T., and Isono, K. (1997) Identification and characterization of the genes for mitochondrial ribosomal proteins of *Saccharomyces cerevisiae*. *Eur. J. Biochem.* **245**, 449–456 [CrossRef Medline](#)
45. Neupert, W., and Herrmann, J. M. (2007) Translocation of proteins into mitochondria. *Annu. Rev. Biochem.* **76**, 723–749 [CrossRef Medline](#)
46. Chacinska, A., Koehler, C. M., Milenkovic, D., Lithgow, T., and Pfanner, N. (2009) Importing mitochondrial proteins: Machineries and mechanisms. *Cell* **138**, 628–644 [CrossRef Medline](#)
47. Gambill, B. D., Voos, W., Kang, P. J., Miao, B., Langer, T., Craig, E. A., and Pfanner, N. (1993) A dual role for mitochondrial heat shock protein 70 in membrane translocation of preproteins. *J. Cell Biol.* **123**, 109–117 [CrossRef Medline](#)
48. Mihara, K., and Omura, T. (1996) Cytosolic factors in mitochondrial protein import. *Experientia* **52**, 1063–1068 [CrossRef Medline](#)
49. Mori, M., and Terada, K. (1998) Mitochondrial protein import in animals. *Biochim. Biophys. Acta* **1403**, 12–27 [CrossRef Medline](#)
50. Mihara, K., and Omura, T. (1996) Cytoplasmic chaperones in precursor targeting to mitochondria: The role of MSF and hsp 70. *Trends Cell Biol.* **6**, 104–108 [CrossRef Medline](#)
51. Deshaies, R. J., Koch, B. D., Werner-Washburne, M., Craig, E. A., and Schekman, R. (1988) A subfamily of stress proteins facilitates translocat-

- tion of secretory and mitochondrial precursor polypeptides. *Nature* **332**, 800–805 [CrossRef Medline](#)
52. Murakami, H., Pain, D., and Blobel, G. (1988) 70-kD heat shock-related protein is one of at least two distinct cytosolic factors stimulating protein import into mitochondria. *J. Cell Biol.* **107**, 2051–2057 [CrossRef Medline](#)
 53. Becker, J., Walter, W., Yan, W., and Craig, E. A. (1996) Functional interaction of cytosolic hsp70 and a DnaJ-related protein, Ydj1p, in protein translocation *in vivo*. *Mol. Cell Biol.* **16**, 4378–4386 [CrossRef Medline](#)
 54. Terada, K., Ohtsuka, K., Imamoto, N., Yoneda, Y., and Mori, M. (1995) Role of heat shock cognate 70 protein in import of ornithine transcarbamylase precursor into mammalian mitochondria. *Mol. Cell Biol.* **15**, 3708–3713 [CrossRef Medline](#)
 55. Sheffield, W. P., Shore, G. C., and Randall, S. K. (1990) Mitochondrial precursor protein. Effects of 70-kilodalton heat shock protein on polypeptide folding, aggregation, and import competence. *J. Biol. Chem.* **265**, 11069–11076 [Medline](#)
 56. Buchberger, A., Bukau, B., and Sommer, T. (2010) Protein quality control in the cytosol and the endoplasmic reticulum: brothers in arms. *Mol. Cell* **40**, 238–252 [CrossRef Medline](#)
 57. Amm, L., Sommer, T., and Wolf, D. H. (2014) Protein quality control and elimination of protein waste: The role of the ubiquitin-proteasome system. *Biochim. Biophys. Acta* **1843**, 182–196 [CrossRef Medline](#)
 58. Ghislain, M., Udvardy, A., and Mann, C. (1993) *S. cerevisiae* 26S protease mutants arrest cell division in G2/metaphase. *Nature* **366**, 358–362 [CrossRef Medline](#)
 59. Rassow, J., Hartl, F. U., Guiard, B., Pfanner, N., and Neupert, W. (1990) Polypeptides traverse the mitochondrial envelope in an extended state. *FEBS Lett.* **275**, 190–194 [CrossRef Medline](#)
 60. Wrobel, L., Topf, U., Bragoszewski, P., Wiese, S., Sztolszterer, M. E., Oeljeklaus, S., Varabyova, A., Lirski, M., Chroszczicki, P., Mroczek, S., Januszewicz, E., Dziembowski, A., Koblowska, M., Warscheid, B., and Chacinska, A. (2015) Mistargeted mitochondrial proteins activate a proteostatic response in the cytosol. *Nature* **524**, 485–488 [CrossRef Medline](#)
 61. Wang, X., and Chen, X. J. (2015) A cytosolic network suppressing mitochondria-mediated proteostatic stress and cell death. *Nature* **524**, 481–484 [CrossRef Medline](#)
 62. D'Amico, D., Sorrentino, V., and Auwerx, J. (2017) Cytosolic proteostasis networks of the mitochondrial stress response. *Trends Biochem. Sci.* **42**, 712–725 [CrossRef Medline](#)
 63. Wang, Z., and Prelich, G. (2009) Quality control of a transcriptional regulator by SUMO-targeted degradation. *Mol. Cell Biol.* **29**, 1694–1706 [CrossRef Medline](#)
 64. Liebelt, F., and Vertegaal, A. C. (2016) Ubiquitin-dependent and independent roles of SUMO in proteostasis. *Am. J. Physiol. Cell Physiol.* **311**, C284–C296 [CrossRef Medline](#)
 65. Krumova, P., and Weishaupt, J. H. (2013) Sumoylation in neurodegenerative diseases. *Cell Mol. Life Sci.* **70**, 2123–2138 [CrossRef Medline](#)
 66. Janer, A., Werner, A., Takahashi-Fujigasaki, J., Daret, A., Fujigasaki, H., Takada, K., Duyckaerts, C., Brice, A., Dejean, A., and Sittler, A. (2010) SUMOylation attenuates the aggregation propensity and cellular toxicity of the polyglutamine expanded ataxin-7. *Hum. Mol. Genet.* **19**, 181–195 [CrossRef Medline](#)
 67. Krumova, P., Meulmeester, E., Garrido, M., Tirard, M., Hsiao, H. H., Bossis, G., Urlaub, H., Zweckstetter, M., Kügler, S., Melchior, F., Bähr, M., and Weishaupt, J. H. (2011) Sumoylation inhibits α -synuclein aggregation and toxicity. *J. Cell Biol.* **194**, 49–60 [CrossRef Medline](#)
 68. Mukherjee, S., Thomas, M., Dadgar, N., Lieberman, A. P., and Iñiguez-Lluhi, J. A. (2009) Small ubiquitin-like modifier (SUMO) modification of the androgen receptor attenuates polyglutamine-mediated aggregation. *J. Biol. Chem.* **284**, 21296–21306 [CrossRef Medline](#)
 69. Steffan, J. S., Agrawal, N., Pallos, J., Rockabrand, E., Trotman, L. C., Slepko, N., Illes, K., Lukacsovich, T., Zhu, Y. Z., Cattaneo, E., Pandolfi, P. P., Thompson, L. M., and Marsh, J. L. (2004) SUMO modification of Huntingtin and Huntington's disease pathology. *Science* **304**, 100–104 [CrossRef Medline](#)
 70. Abeywardana, T., and Pratt, M. R. (2015) Extent of inhibition of α -synuclein aggregation *in vitro* by SUMOylation is conjugation site- and SUMO isoform-selective. *Biochemistry* **54**, 959–961 [CrossRef Medline](#)
 71. Zhang, Y. Q., and Sarge, K. D. (2008) Sumoylation of amyloid precursor protein negatively regulates A β aggregate levels. *Biochem. Biophys. Res. Commun.* **374**, 673–678 [CrossRef Medline](#)
 72. Guo, L., Giasson, B. I., Glavis-Bloom, A., Brewer, M. D., Shorter, J., Gitler, A. D., and Yang, X. (2014) A cellular system that degrades misfolded proteins and protects against neurodegeneration. *Mol. Cell* **55**, 15–30 [CrossRef Medline](#)
 73. Jentsch, S., and Psakhye, I. (2013) Control of nuclear activities by substrate-selective and protein-group SUMOylation. *Annu. Rev. Genet.* **47**, 167–186 [CrossRef Medline](#)
 74. Olsen, J. V., de Godoy, L. M., Li, G., Macek, B., Mortensen, P., Pesch, R., Makarov, A., Lange, O., Horning, S., and Mann, M. (2005) Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. *Mol. Cell Proteomics* **4**, 2010–2021 [CrossRef Medline](#)
 75. Cox, J., and Mann, M. (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nat. Biotechnol.* **26**, 1367–1372 [CrossRef Medline](#)
 76. Knop, M., Siegers, K., Pereira, G., Zachariae, W., Winsor, B., Nasmyth, K., and Schiebel, E. (1999) Epitope tagging of yeast genes using a PCR-based strategy: More tags and improved practical routines. *Yeast* **15**, 963–972 [CrossRef Medline](#)
 77. Janke, C., Magiera, M. M., Rathfelder, N., Taxis, C., Reber, S., Maekawa, H., Moreno-Borchart, A., Doenges, G., Schwob, E., Schiebel, E., and Knop, M. (2004) A versatile toolbox for PCR-based tagging of yeast genes: New fluorescent proteins, more markers and promoter substitution cassettes. *Yeast* **21**, 947–962 [CrossRef Medline](#)
 78. Sherman, F. (1991) Getting started with yeast. *Methods Enzymol.* **194**, 3–21 [CrossRef Medline](#)
 79. Hoege, C., Pfander, B., Moldovan, G. L., Pyrowolakis, G., and Jentsch, S. (2002) RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. *Nature* **419**, 135–141 [CrossRef Medline](#)
 80. Sacher, M., Pfander, B., Hoege, C., and Jentsch, S. (2006) Control of Rad52 recombination activity by double-strand break-induced SUMO modification. *Nat. Cell Biol.* **8**, 1284–1290 [CrossRef Medline](#)
 81. Fang, N. N., Ng, A. H., Measday, V., and Mayor, T. (2011) Hul5 HECT ubiquitin ligase plays a major role in the ubiquitylation and turnover of cytosolic misfolded proteins. *Nat. Cell Biol.* **13**, 1344–1352 [CrossRef Medline](#)